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Some glass ceilings are waiting to be broken.  If you are a follower of Chris 
Lipinski’s rules(1) then you should probably stop reading: any commentary 
about macrocyclic drugs is likely to induce nausea, dizziness and disbelief in 
devotees.  The rules were of course derived from a dataset of known orally 
bioavailable drugs and represents a snapshot in time: dataset selection is 
everything in this field and is the elephant in the room. Empirically derived rules 
are tautologies and we shouldn’t be surprised when they are broken once we 
step outside of the dataset(2).   
 
The most fragile part of this particular glass ceiling is the molecular weight limit 
of 500 Da; a limit easily smashed by modern blockbuster drugs and some older 
former blockbuster macrocycles such as cyclosporine 1 (Figure 1).  As medicinal 
chemistry has developed and encompassed protein-protein interaction targets 
so the size of molecules has increased over time leading to the beyond Ro5 or 
bRo5 concept (3).  This trend was first evident with the HIV protease inhibitors 
such as saquinavir 2, but continues to the present day with the new BCl2 
inhibitor ABT-199, ventoclax 3, the HCV drug velpatasvir 4 and many other 
natural product examples (Figure 1).  
 
Figure 1, Figure 2 
 
Verteporfin 5 (Figure 2) is a photodynamic therapy drug delivered intravenously 
for the treatment of AMD in conjuction with red light and is therefore outside of 
normal considerations of orally bioavailable drug likeness space.  Verteporfin 
and similar therapies still have to cross cell membranes however, have an 
acceptable toxicity profile, be formulated adequately, and achieve active 
concentrations at the target site. All these are in fact drug-likeness 
characteristics in the wider sense.  This special issue describes the use of 
macrocycles in different aspects of drug use from photodynamic therapy to 
potential new antibiotics, formulation uses and imaging.  Macrocycles can 
interact with a greater variety of protein targets and have many more 
applications than small molecules which makes them ideal for new therapies. 
Our tendency as medicinal chemists is to look at the molecules in Table 1 and see 
them as outliers whereas in reality they are the forerunners of many more drugs 
to follow. We are learning to understand such molecules however(4) but much 
more remains to be done.   
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This macrocyclefest is a celebration of the creativity and dedication of organic  
and medicinal chemists, often drawing on inspiration from nature but also open 
to the limitless inventiveness for the development of new structures and 
applications. These molecules stretch our preconceptions of drug-likeness 
chemical space – and this is no bad thing. 
 
In the review by Richard S. Brzozowski and William M. Wuest(5) the authors 
argue that 12 membered ring lactones are “privileged scaffolds” whose potential 
as biologically active molecules and potential drugs is still unrealized.  
Chemically fascinating, these structures show diverse chemistry and biological 
activities.  Of course macrocyclic lactones are well known and the macrolide 
antibiotic drugs such as erythromycin 6 are mainstays of therapy.  The authors 
show biosynthesis, synthetic methods and describe biological activity.  A notable 
example is carolacton 7 (Figure 3) a highly potent bacterial biofilm inhibitor(6) 
which was synthesized by the Wuest group in 14 steps(7). Though this is still a 
little long for a drug candidate it represents a useful synthetic route that could 
with adaptations be utilized for analogue preparation.  Perhaps this is the most 
tantalizing aspect of the 12 membered ring class, they are, thanks to the heroic 
efforts of synthetic chemists and the many advances in chemical methods, 
amenable to chemical synthesis.  This will allow their properties and activities to 
be optimized and adjusted for different targets and drug uses. The crystal 
structure shows a relatively compact structure for the core ring with the side 
chain providing facility to make more extended contacts(8).   
 
 
Figure 3 
 
 
In the review by the Michael Hamblin(9) and co-workers tetrapyrrole 
photosensitizer design features are described.  The authors point out that the 
molecules are usually delivered by intravenous injection and highly lipophilic 
molecules are favoured over hydrophilic ones. In contrast to most drugs the 
molecules do not bind specific proteins but rather are localized to different 
organelles within the cell for example APSC 12, 8 initially localizes to liposomes 
but on photoactivation relocalizes to ribosomes where it kills the cell(10). In 
contrast the cationic species such as 9 tend to relocalise to  mitochondria(11) 
(Figure 4).  
 
 
Figure 4 
 
 
The photosensitizer theme is continued in an original article by Homem-de-
Mello(12) and co-workers where density functional theory is utilized to for 
analysis and a number of chemical descriptors (molecular volume, LUMO energy, 
oscillator strength, dipole moment and free energy of solvation) are proposed as 
useful in separating or classifying pthalocyanine photosensitizers. The study 
included the clinical agent verteporfin 5 (Visudyne) and a range of experimental 
molecules.  
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The review by Horne and Cronjé(13) discusses mechanistic aspects of 
photosensitizer design and the wider photosensiter classes and also goes into 
detail on some of the shortcomings and difficulties of formulation of such 
lipophilic structures. Liposomes, cyclodextrins and lipoproteins are all discussed 
as formulation aids. Photosensitizers may not be delivered orally but the 
constraints imposed by crossing membranes are still evident. The summary of 
the different light sources utilized is also particularly illuminating for the non-
expert.  
 
The use of macrocycles as scaffolds is highlighted by Naseer(14) and co-
workers with a review on therapeutic potential of calix[4]arenes.  Calix[4]arenes 
are well known for their well defined central cavity and host-guest properties 
but the potential of these structures as molecular scaffolds for biologically active 
molecules is less well appreciated.  Of the many examples given I was struck by 
the potent tuberculosis activity of the guanidine functionalized molecules 
exemplified by CX1 (Figure 5).  These molecules were designed as analogues of 
the anti-microbial peptides(15).  This ability of calixarenes to display 
supramolecular structures is perhaps their best asset. 
 
Figure 5 
 
 
Another well studied host macrocycle class are reviewed by Ghasemi(16) and 
colleagues but from the aspect of computer aided design.  The ability to 
effectively model cyclodextrin complexes is important given that relatively few 
X-ray structures are known. When structures are available  as for paroxetine 11 
they reveal a (17) beautiful symmetrical and 1:2 arrangement effectively 
shielding the hydrophobic paroxetine from the aqueous medium (Figure 6).  
Unlike calixarenes and tetrapyrroles cyclodextrin macrocycles are notably water 
soluble making them suitable for use as formulation components as well as 
scaffolds.  As Ghasemi and colleagues note they are biocompatible and 
biodegradable and could be expanded to many more applications.  
 
 
Figure 6 
 
 
The next review in this series contains some extraordinary molecules as 
described by Siddappa, Shivaputra and Renukadevi Patil (18); 
(benz)imidazole and indole based macrocycles might seem terribly familiar but 
dicationic structures such as 12 are notably active against bacteria(19).  Away 
from these exotic structures the use of macrocycles in mainstream drug 
discovery is demonstrated by the clinical candidate TMC647055 13, a potent 
inhibitor (77 nM) of the NS5B polymerase from hepatitis C virus(20) (Figure 7).   
 
Figure 7 
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This series completes with two original articles, in the first Jasleen Kaur(21) 
and co-workers outline the synthesis of a DO3A based macrocycle 14 for MRI 
imaging and potential theranostic use (Figure 8).  The compound demonstrated 
high relaxivity 7.1 mM-1s-1 superior to some standard agents.  In the second 
article Zhang(22) and colleagues prepare a 99mTc(CO)3 –glucose conjugate 15 
utilizing click chemistry and determined good tumour localization opening up 
the possibility of using this molecule as a tumour imaging agent. 
 
Figure 8 
 
 
 
 
 
 
 
 
 
 
Table 1. Comparison of Lipinski Ro5 with PPI inhibitors and macrocyclic drugs.  
 
Parameter 
 
Lipinki’s rule of 
fives: Small 
molecule drugs 
Ventoclax Cyclosporine 
 
Verteporfin 
(pdt therapy) 
CLogP <5 
10.3 
(XlogP 
8.2) 
2.7* 5.9 
Hydrogen bond 
donors (NH + 
OH) 
<5 3 5 2 
Molecular 
weight 
<500 868 1202 718 
Hydrogen bond 
acceptors 
<10 14 12 12 
tPSA# <140 176 279 165 
See figures for structures.  *Experimentally determined see ref(23), #Veber’s PSA 
limit. 
 
 
 
Figure Legends 
 
Figure 1.  Breaking the glass Lipinski ceiling, high molecular weight drugs. 
 
Figure 2. The i.v. injectable photodynamic therapy drug verteporfin. 
 
Figure 3. Structures of erythromycin, carolacton and the carolacton 
crystal structure. Structure CCDC 735883 was downloaded and visualized with 
MOE. 
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Figure 4. Tetrapyrrole photosynthesisers APSC, and the cationic 
photosynthesiser 9. 
 
Figure 5.  Guanidine functionalized calix[4]arene. 
 
Figure 6. Structure of paroxetine and X-ray structure of the cyclodextrin 
complex as side and top view. Structure CCDC 184570 was downloaded and 
visualized with MOE. 
 
Figure 7. Antibacterial indole based dication 12 and hepatitis C virus NS5B 
polymerase inhibitor TMC647055. 
 
Figure 8. Macrocycle based chelating agents for MRI and SPECT/CT imaging 
applications. 
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